Afamelanotide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Erythropoietic Protoporphyria
Conditions
Erythropoietic Protoporphyria
Trial Timeline
May 1, 2007 → Dec 9, 2009
NCT ID
NCT04053270About Afamelanotide + Placebo
Afamelanotide + Placebo is a phase 3 stage product being developed by Clinuvel Pharmaceuticals for Erythropoietic Protoporphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT04053270. Target conditions include Erythropoietic Protoporphyria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04525157 | Phase 2 | Completed |
| NCT01605136 | Phase 3 | Completed |
| NCT04704713 | Phase 3 | Completed |
| NCT01097044 | Phase 2 | Completed |
| NCT00979745 | Phase 3 | Completed |
| NCT04425746 | Phase 2 | Completed |
| NCT04053270 | Phase 3 | Completed |
Competing Products
8 competing products in Erythropoietic Protoporphyria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DISC-1459 + DISC-1459 + Placebo | Disc Medicine | Phase 2 | 47 |
| Placebo + DISC-1459 | Disc Medicine | Phase 3 | 72 |
| DISC-1459 + DISC-1459 | Disc Medicine | Phase 2/3 | 60 |
| Afamelanotide | Clinuvel Pharmaceuticals | Phase 3 | 69 |
| Afamelanotide 16mg implant | Clinuvel Pharmaceuticals | Phase 1/2 | 33 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 69 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 2 | 44 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 69 |